KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Capital Leases (2016 - 2021)

Historic Capital Leases for Neogenomics (NEO) over the last 13 years, with Q4 2021 value amounting to $71000.0.

  • Neogenomics' Capital Leases fell 9265.77% to $71000.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $71000.0, marking a year-over-year decrease of 9265.77%. This contributed to the annual value of $71000.0 for FY2021, which is 9265.77% down from last year.
  • Per Neogenomics' latest filing, its Capital Leases stood at $71000.0 for Q4 2021, which was down 9265.77% from $152000.0 recorded in Q3 2021.
  • Over the past 5 years, Neogenomics' Capital Leases peaked at $11.5 million during Q4 2018, and registered a low of $71000.0 during Q4 2021.
  • Moreover, its 5-year median value for Capital Leases was $4.3 million (2017), whereas its average is $3.8 million.
  • Per our database at Business Quant, Neogenomics' Capital Leases surged by 11858.79% in 2018 and then tumbled by 9265.77% in 2021.
  • Neogenomics' Capital Leases (Quarter) stood at $5.3 million in 2017, then surged by 118.59% to $11.5 million in 2018, then crashed by 72.3% to $3.2 million in 2019, then tumbled by 69.77% to $967000.0 in 2020, then crashed by 92.66% to $71000.0 in 2021.
  • Its Capital Leases stands at $71000.0 for Q4 2021, versus $152000.0 for Q3 2021 and $448000.0 for Q2 2021.